目的运用质谱分析、网络药理学和动物实验探讨健脑固本方治疗脑小血管病性认知障碍(cerebral small vessel disease,CSVCI)的作用机制。方法通过质谱分析得出主要活性成分,TCMSP检索其相应作用靶点;通过GeneCards、OMIM数据库检索CSVCI...目的运用质谱分析、网络药理学和动物实验探讨健脑固本方治疗脑小血管病性认知障碍(cerebral small vessel disease,CSVCI)的作用机制。方法通过质谱分析得出主要活性成分,TCMSP检索其相应作用靶点;通过GeneCards、OMIM数据库检索CSVCI疾病靶点;通过String数据库和Cytoscape软件构建药物疾病作用靶点网络可视化;利用DAVID数据库对交集靶点进行GO功能和KEGG信号通路富集分析。结果健脑固本方的有效活性成分有山奈酚、薯蓣皂苷,作用于丝裂原活化蛋白激酶8、蛋白激酶B1等核心靶点,可能通过磷脂酰肌醇3-激酶/蛋白激酶B等信号通路涉及炎症反应。蛋白免疫印迹法检测结果表明健脑固本方抑制Notch-1、RBP-Jκ以及Hes-1的表达。结论本研究初步表明健脑固本方能够通过多靶点、多通路、多途径治疗CSVCI,具体作用机制可能是抑制Notch-1信号通路,进而抑制炎症反应。展开更多
目的对舒肝解郁胶囊治疗抑郁症的系统评价(SR)/Meta分析(MA)进行再评价,以期为临床实践提供证据支持。方法计算机检索中国知识资源总库(CNKI)、万方数据知识服务平台(万方数据)、中文科技期刊数据库(维普网)、中国生物医学文献数据库(C...目的对舒肝解郁胶囊治疗抑郁症的系统评价(SR)/Meta分析(MA)进行再评价,以期为临床实践提供证据支持。方法计算机检索中国知识资源总库(CNKI)、万方数据知识服务平台(万方数据)、中文科技期刊数据库(维普网)、中国生物医学文献数据库(CBM)、PubMed、Web of Science、Cochrane Library数据库,并查询Clinical Trials.gov和中国临床试验注册中心两大临床试验注册系统,收集舒肝解郁胶囊治疗抑郁症的中英文文献,检索时间范围自建库至2022年2月。对最终纳入的SR/MA使用AMSTAR-2量表、PRISMA声明及GRADE系统分别进行方法学质量评价、报告质量评价和证据等级评价。结果共纳入11篇SR/MA,36个临床结局指标。AMSTAR-2评价结果显示,11篇SR/MA中1篇为低质量,其余10篇均为极低质量。PRISMA声明评价结果显示,9篇SR/MA报告质量评分15~20分,报告有一定缺陷;2篇SR/MA<15分,报告信息缺陷严重。GRADE系统对36个临床结局指标进行质量评价,结果为中级证据4个,其余为低级或极低级证据,4个中级证据中1个采用治愈率,2个采用有效率,1个采用不良反应。结论舒肝解郁胶囊治疗抑郁症疗效较好,不良反应少,但证据水平有待提高。舒肝解郁胶囊治疗抑郁症的有效性和安全性仍需更多高质量研究进一步验证,相关SR/MA制作应重视报告规范。展开更多
OBJECTIVE:To summarize the evidence from Traditional Chinese Medicine(TCM)practice in the treatment of acute primary headache and provide clinical practice guidance.METHODS:The guidelines were developed in accordance ...OBJECTIVE:To summarize the evidence from Traditional Chinese Medicine(TCM)practice in the treatment of acute primary headache and provide clinical practice guidance.METHODS:The guidelines were developed in accordance with the World Health Organization guideline development manual.After the establishment of steering committee,panel and the registration and protocol formulation,the evidence on TCM for acute primary headache from published guidelines,clinical evidence,and expert experience and consensus were collected.The grading of recommendations assessment,development and evaluation method was used to grade the evidence and make the recommendations.RESULTS:Based on the available evidence,the guidelines recommended three TCM herbal decoctions,six Chinese patent medicines,and two kinds of external application of Chinese herbal medicines.Diagnostic recommendations based on the expert experience and consensus were also included in the guidelines.CONCLUSION:TCM diagnosis and treatment of decoction,Chinese patent medicine and external application for treating acute primary headache were recommended.We hope these guidelines will be helpful in standardize the TCM acute treatment of primary headache.展开更多
OBJECTIVE:To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms,a randomized,double-blind,double-dummy controlled,multicenter,parallel-treatment trial...OBJECTIVE:To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms,a randomized,double-blind,double-dummy controlled,multicenter,parallel-treatment trial was carried out among 210 outpatients with mild to moderate depression and anxiety symptoms from three hospitals in Beijing China.METHODS:Participants were randomized into the JWXY group or the sertraline group.Each group received JWXY treatment and sertraline placebo,or sertraline and JWXY placebo for 8 weeks.Main outcomes were measured using the Hamilton Depression Rating Scale (HAMD),Hamilton Anxiety Rating Scale (HAMA) and the Clinical Global Impression Scale.RESULTS:JWXY and sertraline had the equivalent effect on HAMD at every interview point.JWXY was more effective at reducing the HAMA scores at the 2nd and 12th week,HAMD sleep disturbance subscale scores at the 8th and 12th week,and HAMA somatic anxiety subscale scores at the 12th week.The rate of adverse events in the two groups was the same.CONCLUSION:For mild to moderate depression with anxiety symptoms,JWXY could be as effective as sertraline in alleviating depressive symptoms.For anxiety symptoms,JWXY may be effective more quickly and with longer lasting effects than sertraline.In particular,it may also improve quality of sleep and somatic anxiety symptoms.JWXY is safe and cheaper than conventional antidepressants,and may be the first alternative choice for depression with anxiety symptoms.展开更多
文摘目的运用质谱分析、网络药理学和动物实验探讨健脑固本方治疗脑小血管病性认知障碍(cerebral small vessel disease,CSVCI)的作用机制。方法通过质谱分析得出主要活性成分,TCMSP检索其相应作用靶点;通过GeneCards、OMIM数据库检索CSVCI疾病靶点;通过String数据库和Cytoscape软件构建药物疾病作用靶点网络可视化;利用DAVID数据库对交集靶点进行GO功能和KEGG信号通路富集分析。结果健脑固本方的有效活性成分有山奈酚、薯蓣皂苷,作用于丝裂原活化蛋白激酶8、蛋白激酶B1等核心靶点,可能通过磷脂酰肌醇3-激酶/蛋白激酶B等信号通路涉及炎症反应。蛋白免疫印迹法检测结果表明健脑固本方抑制Notch-1、RBP-Jκ以及Hes-1的表达。结论本研究初步表明健脑固本方能够通过多靶点、多通路、多途径治疗CSVCI,具体作用机制可能是抑制Notch-1信号通路,进而抑制炎症反应。
文摘目的对舒肝解郁胶囊治疗抑郁症的系统评价(SR)/Meta分析(MA)进行再评价,以期为临床实践提供证据支持。方法计算机检索中国知识资源总库(CNKI)、万方数据知识服务平台(万方数据)、中文科技期刊数据库(维普网)、中国生物医学文献数据库(CBM)、PubMed、Web of Science、Cochrane Library数据库,并查询Clinical Trials.gov和中国临床试验注册中心两大临床试验注册系统,收集舒肝解郁胶囊治疗抑郁症的中英文文献,检索时间范围自建库至2022年2月。对最终纳入的SR/MA使用AMSTAR-2量表、PRISMA声明及GRADE系统分别进行方法学质量评价、报告质量评价和证据等级评价。结果共纳入11篇SR/MA,36个临床结局指标。AMSTAR-2评价结果显示,11篇SR/MA中1篇为低质量,其余10篇均为极低质量。PRISMA声明评价结果显示,9篇SR/MA报告质量评分15~20分,报告有一定缺陷;2篇SR/MA<15分,报告信息缺陷严重。GRADE系统对36个临床结局指标进行质量评价,结果为中级证据4个,其余为低级或极低级证据,4个中级证据中1个采用治愈率,2个采用有效率,1个采用不良反应。结论舒肝解郁胶囊治疗抑郁症疗效较好,不良反应少,但证据水平有待提高。舒肝解郁胶囊治疗抑郁症的有效性和安全性仍需更多高质量研究进一步验证,相关SR/MA制作应重视报告规范。
基金National Key Research and Development Program of China:Research on the Development and Evaluation of International Standards of Traditional Chinese Medicine(No.2019YFC1712000)。
文摘OBJECTIVE:To summarize the evidence from Traditional Chinese Medicine(TCM)practice in the treatment of acute primary headache and provide clinical practice guidance.METHODS:The guidelines were developed in accordance with the World Health Organization guideline development manual.After the establishment of steering committee,panel and the registration and protocol formulation,the evidence on TCM for acute primary headache from published guidelines,clinical evidence,and expert experience and consensus were collected.The grading of recommendations assessment,development and evaluation method was used to grade the evidence and make the recommendations.RESULTS:Based on the available evidence,the guidelines recommended three TCM herbal decoctions,six Chinese patent medicines,and two kinds of external application of Chinese herbal medicines.Diagnostic recommendations based on the expert experience and consensus were also included in the guidelines.CONCLUSION:TCM diagnosis and treatment of decoction,Chinese patent medicine and external application for treating acute primary headache were recommended.We hope these guidelines will be helpful in standardize the TCM acute treatment of primary headache.
文摘OBJECTIVE:To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms,a randomized,double-blind,double-dummy controlled,multicenter,parallel-treatment trial was carried out among 210 outpatients with mild to moderate depression and anxiety symptoms from three hospitals in Beijing China.METHODS:Participants were randomized into the JWXY group or the sertraline group.Each group received JWXY treatment and sertraline placebo,or sertraline and JWXY placebo for 8 weeks.Main outcomes were measured using the Hamilton Depression Rating Scale (HAMD),Hamilton Anxiety Rating Scale (HAMA) and the Clinical Global Impression Scale.RESULTS:JWXY and sertraline had the equivalent effect on HAMD at every interview point.JWXY was more effective at reducing the HAMA scores at the 2nd and 12th week,HAMD sleep disturbance subscale scores at the 8th and 12th week,and HAMA somatic anxiety subscale scores at the 12th week.The rate of adverse events in the two groups was the same.CONCLUSION:For mild to moderate depression with anxiety symptoms,JWXY could be as effective as sertraline in alleviating depressive symptoms.For anxiety symptoms,JWXY may be effective more quickly and with longer lasting effects than sertraline.In particular,it may also improve quality of sleep and somatic anxiety symptoms.JWXY is safe and cheaper than conventional antidepressants,and may be the first alternative choice for depression with anxiety symptoms.
